Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 0

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-280796

PROSPECTUS SUPPLEMENT

(To Prospectus dated September July 12, 2024)

<div align='center'>Up to $1,397,532

Common Stock</div>

We have entered into an At
The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) relating
to shares of our common stock offered by this prospectus supplement and the accompanying base prospectus. In accordance with the terms
of the Sales Agreement, we may offer and sell from time to time through or to the Agent, as sales agent or principal, shares of our common
stock having an aggregate offering price of up to $1,397,532.

Our common stock is listed
on The Nasdaq Capital Market under the symbol “SXTP.” The last reported sale price of our common stock on The Nasdaq Capital
Market on September 3, 2025, was $1.46 per share.

We are a “smaller reporting
company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, and, as such, have elected to comply with
certain reduced public company reporting requirements.

Sales of our common stock,
if any, under this prospectus supplement and the accompanying base prospectus will be made through a sale that is deemed to be an “at
the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”).
The Agent is not required to sell any specific amount of our common stock but will act as our sales agent and use commercially reasonable
efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with their normal sales and trading
practices, on mutually agreed terms between the Agent and us. There is no arrangement for funds to be received in an escrow, trust or
similar arrangement.

The Agent will receive from
us a commission of 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale
of our common stock on our behalf, the Agent will be deemed to be an “underwriter” within the meaning of the Securities Act
and the compensation of the Agent will be deemed to be underwriting discounts or commissions. We have agreed to